Mode of primary cancer detection as an indicator of screening practice for second primary cancer in cancer survivors: a nationwide survey in Korea

Beomseok Suh1, Dong Wook Shin1,2†, So Young Kim3, Jae-Hyun Park4, Weon Young Chang5, Seung Pyung Lim6, Chang-Yeol Yim7, Be-Long Cho1,2, Eun-Cheol Park8 and Jong-Hyock Park3,9†

Abstract

Background: While knowledge and risk perception have been associated with screening for second primary cancer (SPC), there are no clinically useful indicators to identify who is at risk of not being properly screened for SPC. We investigated whether the mode of primary cancer detection (i.e. screen-detected vs. non-screen-detected) is associated with subsequent completion of all appropriate SPC screening in cancer survivors.

Methods: Data were collected from cancer patients treated at the National Cancer Center and nine regional cancer centers across Korea. A total of 512 cancer survivors older than 40, time since diagnosis more than 2 years, and whose first primary cancer was not advanced or metastasized were selected. Multivariate logistic regression was used to examine factors, including mode of primary cancer detection, associated with completion of all appropriate SPC screening according to national cancer screening guidelines.

Results: Being screen-detected for their first primary cancer was found to be significantly associated with completion of all appropriate SPC screening (adjusted odds ratio, 2.13; 95% confidence interval, 1.36–3.33), after controlling for demographic and clinical variables. Screen-detected cancer survivors were significantly more likely to have higher household income, have other comorbidities, and be within 5 years since diagnosis.

Conclusions: The mode of primary cancer detection, a readily available clinical information, can be used as an indicator for screening practice for SPC in cancer survivors. Education about the importance of SPC screening will be helpful particularly for cancer survivors whose primary cancer was not screen-detected.

Keywords: Cancer survivor, Second primary cancer, Screening, Mode of detection, Screen-detected

Background

With unprecedented innovation in detection, diagnosis, and treatment for cancer over the recent years, the overall survival rate for cancer has significantly increased [1]. As a result, the number of cancer survivors more than tripled from 1970 to 2000, totaling around 11.1 million in the US [2], and cancer survivorship is becoming more and more an important clinical topic [3]. Among various aspects of this survivorship, screening for second primary cancer (SPC) is an important topic. Cancer survivors are at higher risk to develop cancer [4,5], and SPC is associated with increased mortality [6]. Therefore, early detection by screening for SPC may be an effective way to lower the mortality of cancer survivors as a whole.

Previous studies show that cancer survivors are more likely to undergo cancer screening compared to people without cancer [7-9], nonetheless, the rate was shown to be suboptimal [10]. Some factors [10-12] have been shown to be associated with screening behaviors in cancer survivors, including knowledge and risk perception regarding SPC. However, these factors are rather an array of conceptual and subjective information of a patient that are not always clearly assessable by doctors in
In this study, we investigated whether the mode of primary cancer detection (i.e. screen-detected vs. non-screen-detected) is associated with subsequent completion of all appropriate second primary cancer (SPC) screening in cancer survivors. We also investigated factors associated to the mode of primary cancer detection in order to evaluate other possible indicators that may be involved in the screening behavior of cancer survivors.

Methods

Participants and procedures

This study was performed as a part of an annual national survey to investigate the experience of cancer survivors. This study was approved by the Institutional Review Board of the National Cancer Center in Korea.

Using the quota sampling method, patients were recruited from 10 cancer centers (one national cancer center and the regional cancer centers in each of the nine Korean provinces) in Korea so that the perspective of patients with cancer common to Koreans, as well as that of patients of different gender and ages was represented as fairly as possible. Patients were included in this study if they were older than 18 years of age, used the inpatient or outpatient facilities of at least one of these 10 cancer centers, and agreed to participate. About 200 patients were recruited from each of the 10 cancer centers. To reflect national prevalence of each cancer types, 80% of the recruited patients were to be of the six major types of cancer (stomach, lung, liver, colon and rectal, breast, and cervical) and 20% of others.

Pilot surveys in each cancer center were first conducted using the survey methods employed in this study. No problems were found in the pilot study with patient understanding of the questions or with face or content validity of the questionnaires. Over a period of two months, cancer patients who gave written informed consent to participate in the study were interviewed by trained evaluators. A total of 1,956 cancer patients from the 10 cancer centers completed the interview process. In addition to the survey, medical chart audits were performed to obtain histological and Surveillance Epidemiology and End Results (SEER) stage information (version 2000) [13].

For our study purposes in this particular study, from the original total of 1,956 cancer patients, we excluded patients younger than age 40 (N = 138), in order to specifically analyze the subpopulation of patients recommended to be screened regularly by the current guidelines in Korea (details of the guidelines described in the “Measures and outcomes” section below). Patients with advanced disease, namely those diagnosed with recurrent or distant disease in respect to SEER staging, were excluded (N = 429), because the benefit of screening in those patients is limited due to their low 5-year survival rates. Patients with time since diagnosis less than 2 years were also excluded (N = 877) because in our outcome variable, completion of appropriate screening, screening is recommended at least every 2 years, and screening tests should be performed after cancer diagnosis. Of the original 1,956 subjects, 1,444 subjects were excluded and the final number of subjects for analysis was 512 (Figure 1).

Measures and outcomes

The mode of detection of the cancer survivors’ first primary cancer, which is our main explanatory variable of interest, was determined by a survey question of “How was your cancer discovered?”, for which the answer choices were: (1) “I had a certain symptom of discomfort that prompted me to visit the hospital”; (2) “My cancer was discovered incidentally through routine screening”; (3) “My cancer was discovered incidentally while being tested for another condition”; and (4) “Others.” We defined “screen-detected” cancer patients as those who answered this question as (2) “My cancer was discovered incidentally through routine screening,” and defined “non-screen-detected” cancer patients as those who answered otherwise.

Questions regarding screening practices were adopted from the Korean National Health and Nutrition Survey (KNHANES) [14], and addressed whether individuals had ever undergone examinations for breast cancer (mammogram or breast sonography), stomach cancer (endoscopy or upper gastrointestinal series), cervical cancer (Papanicolaou test), or colorectal cancer (fecal occult blood test, sigmoidoscopy, colonoscopy, or barium enema). A positive answer to any screening question was followed by questions about the timing of the...
most recent examination (<1 year, 1–2 years, 2–5 years, >5 years, or none). We used “completion of all appropriate screening” as the main study outcome variable. Because to our knowledge there is no consensus regarding the optimal cancer screening strategy in Korean cancer survivors, an operational definition of appropriate screening in the current study was developed based on the National Cancer Screening Program in Korea [15]: (1) endoscopy or upper gastrointestinal series in the previous 2 years for stomach cancer screening (age ≥ 40); (2) sigmoidoscopy, colonoscopy, or barium enema in the previous 5 years for colorectal cancer screening (age ≥ 50); (3) mammogram or breast sonography in the previous 2 years for breast cancer screening (age ≥ 40); (4) Papanicolaou test in the previous 2 years for cervical cancer screening (age ≥ 30). Moreover, cancer survivors with specific first primary cancer that the screening aimed to detect were excluded from each calculation [9] (e.g. gastric cancer screening for gastric cancer patients were discarded), because such follow-up exams are carried out to monitor recurrence, rather than screen for SPC.

The survey also included socio-demographic factors known to be associated with screening practices, including age [16,17], gender [18], marital status [16,19], education [16,17,20], monthly household income [19,21,22], smoking status [17], and alcohol consumption [22]. Medical factors included type of cancer, SEER stage, comorbidity, and time since diagnosis. Information regarding the presence of comorbidities was also collected because such conditions are associated with cancer screening practices [20,23] and included hypertension, dyslipidemia, diabetes, osteoarthritis, rheumatoid arthritis, and cerebrovascular, cardiovascular, chronic liver, lung, kidney, or gastrointestinal diseases. Clinical variables, including the date of the primary cancer diagnosis, and stage of disease at the time of diagnosis were collected through review of medical records.

**Statistical analyses**

Descriptive statistics were used to report screening practices of cancer survivors. We developed two multivariate logistic regression models: one to examine the factors associated with the completion of all appropriate screening, and the other to examine the factors associated with the mode of detection. Missing data were <1% for all variables. All analyses were conducted using STATA version 11.0. Statistical significance was specified when p-values were <0.05.

**Results**

**Study population**

The mean age of the study subjects was 59.6 ± 10.2 years; 265 (51.8%) were 60 years of age or older, and 250 (48.8%) were male. Stomach cancer was the most common diagnosis, followed by breast and colorectal cancer. Mean time since cancer diagnosis was 5.1 ± 3.3 years (Table 1).

**SPC screening practices**

The overall SPC screening rate with the age and time corresponding to the guidelines of each cancer for stomach, colorectal, breast, and cervical cancer were 37.9%, 39.2%, 29.0%, 53.4%, respectively (Table 2). Completion rate of all appropriate SPC screening was 36.9% (Table 2) for overall, 32.0% for non-screen detected, and 50.4% for screen-detected survivors, respectively (Table 3).

**Factors associated with completion of all SPC screening**

In univariate analysis, younger age (odds ratio [OR], 1.65; 95% confidence interval [95% CI], 1.15–2.37), male gender (OR, 1.76; 95% CI, 1.22–2.53), higher education (OR, 1.89; 95% CI, 1.26–2.83), alcohol consumption (OR, 1.87; 95% CI, 1.13–3.12), and being screen-detected for primary cancer (OR, 2.16; 95% CI, 1.45–3.21) were associated with completion of all appropriate screening. In multivariate-adjusted analysis, younger age (adjusted odds ratio [aOR], 2.09; 95% 95% CI, 1.32–3.31), and being screen-detected (aOR, 2.13; CI, 1.36–3.33) were found to be significantly associated with completion of all appropriate screening. There was also marginal significance with higher education (aOR, 1.57; CI, 0.96–2.57) (Table 3).

**Characteristics of patients by mode of first primary cancer detection**

Screen-detected cancer survivors were significantly more likely to have higher household income (aOR, 2.23; CI, 1.39–3.58), have other comorbidities (aOR, 2.05; CI, 1.29–3.28). Survivors with 5 years or more since diagnosis were less likely to be screen-detected (aOR, 0.60; CI, 0.38–0.94). Prevalence of screen-detected patients were highest among stomach cancer patients, followed by liver, lung, breast, cervical, other, and colorectal cancer patients (36.8%, 33.3%, 30.8%, 29.2%, 21.4%, 19.4%, 16.2%) (Table 4).

**Discussion**

To our knowledge, the current study, carried out with a relatively large nationally representative sample, is the first to examine the association between the mode of primary cancer detection and subsequent SPC screening in cancer survivors. We have shown that the mode of primary cancer detection may be used as a useful clinical indicator for SPC screening practices in cancer survivors. No specific comparison to other related studies for our key finding was possible because our study is the only study that investigated the association between the
mode of primary cancer screening and subsequent SPC screening in cancer survivors, which is a unique setting different from primary cancer screening.
In our study, only 36.9% of cancer survivors completed all age, sex- appropriate screening for SPC. This figure is similar to previous studies performed in Korea [12], and confirms the need to increase screening rates in this population. Therefore, identification of high risk group for non-completion of SPC screening would be meaningful from both clinical and public health care perspectives.

Table 1 Characteristics of study participants

| Socio-demographic characteristics | Medical characteristics |
|-----------------------------------|-------------------------|
| N (%)                             | N (%)                   |
| Age [Mean ± SD] [59.6 ± 10.2 y]   | Cancer types            |
| 40 ≤ y < 60                       | Stomach 106 (20.7)      |
| ≥ 60 y                            | Lung 39 (7.6)           |
| Gender                            | Liver 42 (8.2)          |
| Female                            | Colon/Rectum 74 (14.5)  |
| Male                              | Breast 113 (22.1)       |
| Marital status                    | Cervix 14 (2.7)         |
| Not married (single, divorced, widowed) 87 (17.0) Others 124 (24.2) |
| Married                           | Stage                   |
| Education                         | In situ & local 282 (55.1) |
| Less than high school             | Regional 230 (44.9)     |
| High school and above             | Comorbidity             |
| Monthly household income          | No 189 (36.9)           |
| <2 million won                    | Yes 323 (63.1)          |
| ≥2 million won                    | Years since diagnosis [Mean±SD] [5.1 ± 3.3 y] |
| Insurance                         | Medicaid/none/others 94 (18.4) |
| National health insurance         | 25 y 185 (36.1)         |

Abbreviations: SD standard deviation, N number, y year.

Table 2 Screening practice for second primary cancer among cancer survivors

| Stomach Cancer Survivors* | Lung Cancer Survivors | Liver Cancer Survivors | Colorectal Cancer Survivors* | Breast Cancer Survivors* | Cervical Cancer Survivors* | Other Cancer Survivors | All Survivors |
|--------------------------|-----------------------|------------------------|-------------------------------|--------------------------|----------------------------|------------------------|--------------|
| N (%)                    | N (%)                 | N (%)                  | N (%)                         | N (%)                    | N (%)                      | N (%)                  | N (%)        |
| Men                      | Women N = 113         | Men N = 113            | Women N = 51                  | Men N = 51                | Women N = 63               | Men N = 61             | N = 512      |

Stomach cancer screening
NA NA 12 (40.0) 19 (57.3) 19 (57.3) 7 (35.7) 30 (47.6) 194 (37.9)
Colorectal cancer screening**
32 (57.1) 16 (47.5) 2 (25.0) NA 32 (43.8) 5 (38.5) 23 (39.7) 164 (39.2)
Breast cancer screening***
NA 12 (48.0) NA 2 (62.9) NA 6 (42.9) NA 76 (29.0)
Cervical cancer screening***
NA 14 (56.0) NA 3 (91.1) 69 (61.1) NA 140 (53.4)
Complete cancer screening
45 (55.6) 9 (36.0) 10 (33.3) 6 (26.1) 4 (28.6) 21 (33.3) 189 (36.9)

Abbreviations: NA not applicable, N number.
*Only patients not having the specific type of cancer were included for the cancer screening, e.g. stomach cancer survivors were not subject to stomach cancer screening, etc.
**The overall rate of colorectal cancer screening has been calculated only among subjects of age 50 or more (N = 418). Cancer survivors who were younger than 50 were automatically classified as having completed colorectal cancer screening, because they were not recommended to be screened for colorectal cancer by current guidelines. Hence, male stomach cancer survivors younger than 50 were automatically classified as having completed all appropriate SPC screening without having received any screening exam.
***The overall rates of breast cancer screening and cervical cancer screening have been calculated only among female subjects (N = 262).
| Completion of All Appropriate SPC Screening | No | Yes | Univariate | OR (95% CI) | Multivariate* | OR (95% CI) |
|-------------------------------------------|----|-----|------------|-------------|---------------|-------------|
| **Age**                                   |    |     |            |             |               |             |
| Old (≥ 60 y)                              | 182 (68.7) | 83 (31.3) | 1.00       | 1.00         |               |             |
| Young (40 ≤ y < 60)                       | 141 (57.1) | 106 (42.9) | 1.65 (1.15–2.37) | 2.09 (1.32–3.31) |               |             |
| **Gender**                                |    |     |            |             |               |             |
| Female                                    | 182 (69.5) | 80 (30.5) | 1.00       | 1.00         |               |             |
| Male                                      | 141 (56.4) | 109 (43.6) | 1.76 (1.22–2.53) | 1.45 (0.87–2.41) |               |             |
| **Marital status**                        |    |     |            |             |               |             |
| Not married (single, divorced, widowed)   | 56 (64.4) | 31 (35.6) | 1.00       | 1.00         |               |             |
| Married                                   | 267 (62.8) | 158 (37.2) | 1.07 (0.66–1.73) | 0.69 (0.40–1.21) |               |             |
| **Education**                             |    |     |            |             |               |             |
| Less than high school                     | 120 (72.7) | 45 (27.3) | 1.00       | 1.00         |               |             |
| High school and above                     | 203 (58.5) | 144 (41.5) | 1.89 (1.26–2.83) | 1.57 (0.96–2.57) |               |             |
| **Monthly household income**              |    |     |            |             |               |             |
| <2 million won                            | 233 (65.5) | 128 (35.5) | 1.00       | 1.00         |               |             |
| ≥ 2 million won                           | 90 (59.6) | 61 (40.4) | 1.23 (0.84–1.82) | 0.91 (0.57–1.44) |               |             |
| **Insurance**                             |    |     |            |             |               |             |
| Medicaid/none/others                      | 65 (69.2) | 29 (30.9) | 1.00       | 1.00         |               |             |
| National health insurance                 | 258 (61.7) | 160 (38.3) | 1.39 (0.86–2.25) | 1.46 (0.84–2.52) |               |             |
| **Cancer types**                          |    |     |            |             |               |             |
| Stomach                                   | 52 (49.1) | 54 (50.9) | 1.00       | 1.00         |               |             |
| Lung                                      | 19 (48.7) | 20 (51.3) | 1.01 (0.49–2.11) | 1.46 (0.65–3.27) |               |             |
| Liver                                     | 29 (69.1) | 13 (31.0) | 0.43 (0.20–0.92) | 0.47 (0.21–1.05) |               |             |
| Colon/Rectum                              | 49 (66.2) | 25 (33.8) | 0.49 (0.27–0.91) | 0.57 (0.29–1.12) |               |             |
| Breast                                    | 86 (76.1) | 27 (23.9) | 0.30 (0.17–0.54) | 0.31 (0.15–0.64) |               |             |
| Cervix                                    | 10 (71.4) | 4 (28.6) | 0.39 (0.11–1.31) | 0.65 (0.17–2.48) |               |             |
| Others                                    | 78 (62.9) | 46 (37.1) | 0.67 (0.34–0.96) | 0.72 (0.40–1.28) |               |             |
| **Stage**                                 |    |     |            |             |               |             |
| In situ & local                           | 182 (64.5) | 100 (35.5) | 1.00       | 1.00         |               |             |
| Regional                                  | 141 (61.3) | 89 (38.7) | 1.15 (0.80–1.65) | 1.19 (0.79–1.79) |               |             |
| **Years since diagnosis**                 |    |     |            |             |               |             |
| ≤ 5 y                                     | 200 (61.2) | 127 (38.8) | 1.00       | 1.00         |               |             |
| ≥ 5 y                                     | 123 (66.5) | 62 (33.5) | 0.79 (0.54–1.16) | 0.95 (0.63–1.43) |               |             |
| **Comorbidity**                           |    |     |            |             |               |             |
| No                                        | 124 (65.6) | 65 (34.4) | 1.00       | 1.00         |               |             |
| Yes                                       | 199 (61.6) | 124 (38.4) | 1.19 (0.82–1.73) | 0.94 (0.62–1.42) |               |             |
| **Smoking, current**                      |    |     |            |             |               |             |
| No                                        | 305 (63.4) | 176 (36.6) | 1.00       | 1.00         |               |             |
| Yes                                       | 18 (58.1) | 13 (41.9) | 1.25 (0.60–2.62) | 1.04 (0.46–2.36) |               |             |
| **Drinking, current**                     |    |     |            |             |               |             |
| No                                        | 288 (65.2) | 154 (34.8) | 1.00       | 1.00         |               |             |
| Yes                                       | 35 (50.0) | 35 (50.0) | 1.87 (1.13–3.12) | 1.53 (0.86–2.70) |               |             |
| **Mode of first primary cancer detection**|    |     |            |             |               |             |
| Non-screen-detected                       | 255 (68.0) | 120 (32.0) | 1.00       | 1.00         |               |             |
| Screen-detected                           | 68 (49.6) | 69 (50.4) | 2.16 (1.45–3.21) | 2.13 (1.36–3.33) |               |             |

Abbreviations: N number, y year, OR odds ratio, CI confidence interval.

*Adjusted for all variables in univariate analysis.
| Characteristic                          | Non-screen-detected | Screen-detected | Univariate OR (95% CI) | Multivariate aOR (95% CI) |
|----------------------------------------|---------------------|-----------------|------------------------|--------------------------|
| **Age**                                |                     |                 |                        |                          |
| Old (≥ 60 y)                           | 201 (75.9)          | 64 (24.2)       | 1.00                   | 1.00                     |
| Young (40 ≤ y <60)                     | 174 (70.5)          | 73 (29.6)       | 1.32 (0.89–1.95)       | 0.91 (0.55–1.51)         |
| **Gender**                             |                     |                 |                        |                          |
| Female                                 | 192 (73.3)          | 70 (26.7)       | 1.00                   | 1.00                     |
| Male                                   | 183 (73.2)          | 67 (26.8)       | 1.00 (0.68–1.49)       | 0.99 (0.56–1.74)         |
| **Marital status**                     |                     |                 |                        |                          |
| Not married (single, divorced, widowed)| 67 (77.0)           | 20 (23.0)       | 1.00                   | 1.00                     |
| Married                                | 308 (72.5)          | 117 (27.5)      | 1.27 (0.74–2.19)       | 0.97 (0.53–1.79)         |
| **Education**                          |                     |                 |                        |                          |
| Less than high school                  | 131 (79.4)          | 34 (20.6)       | 1.00 (0.68–1.49)       | 0.99 (0.56–1.74)         |
| High school and above                  | 244 (70.3)          | 103 (29.7)      | 1.68 (1.07–2.62)       | 1.41 (0.83–2.41)         |
| **Monthly household income**           |                     |                 |                        |                          |
| <2 million won                         | 284 (78.7)          | 77 (21.3)       | 1.00                   | 1.00                     |
| ≥ 2 million won                        | 91 (60.3)           | 60 (39.7)       | 2.43 (1.61–3.67)       | 2.23 (1.39–3.58)         |
| **Insurance**                          |                     |                 |                        |                          |
| Medicaid/none/others                   | 74 (78.7)           | 20 (21.28)      | 1.00                   | 1.00                     |
| National health insurance              | 301 (72.0)          | 117 (28.0)      | 1.40 (0.82–2.40)       | 1.17 (0.64–2.15)         |
| **Cancer types**                       |                     |                 |                        |                          |
| Stomach                                | 67 (63.2)           | 39 (36.8)       | 1.00                   | 1.00                     |
| Lung                                   | 27 (69.2)           | 12 (30.8)       | 0.76 (0.35–1.68)       | 0.80 (0.34–1.88)         |
| Liver                                  | 28 (66.7)           | 14 (33.3)       | 0.86 (0.40–1.82)       | 0.85 (0.38–1.90)         |
| Colon/Rectum                           | 62 (83.8)           | 12 (16.2)       | 0.33 (0.16–0.69)       | 0.33 (0.15–0.72)         |
| Breast                                 | 80 (70.8)           | 33 (29.2)       | 0.71 (0.40–1.25)       | 0.56 (0.27–1.17)         |
| Cervix                                 | 11 (78.6)           | 3 (21.4)        | 0.47 (0.12–1.78)       | 0.41 (0.09–1.77)         |
| Others                                 | 100 (80.7)          | 24 (19.4)       | 0.41 (0.23–0.75)       | 0.38 (0.20–0.72)         |
| **Stage**                              |                     |                 |                        |                          |
| In situ & local                        | 203 (72.0)          | 79 (28.0)       | 1.00                   | 1.00                     |
| Regional                               | 172 (74.8)          | 58 (25.2)       | 0.87 (0.58–1.29)       | 0.92 (0.59–1.42)         |
| **Years since diagnosis**              |                     |                 |                        |                          |
| 2 ≤ y <5                               | 231 (70.6)          | 96 (29.4)       | 1.00                   | 1.00                     |
| 2 ≤ y ≥ 5                              | 144 (77.8)          | 41 (22.2)       | 0.69 (0.45–1.04)       | 0.60 (0.38–0.94)         |
| **Comorbidity**                        |                     |                 |                        |                          |
| No                                     | 154 (81.5)          | 35 (18.5)       | 1.00                   | 1.00                     |
| Yes                                    | 221 (68.4)          | 102 (31.6)      | 2.03 (1.31–3.14)       | 2.05 (1.29–3.28)         |
| **Smoking, current**                   |                     |                 |                        |                          |
| No                                     | 350 (72.8)          | 131 (27.2)      | 1.00                   | 1.00                     |
| Yes                                    | 25 (80.7)           | 6 (19.4)        | 0.64 (0.26–1.60)       | 0.68 (0.26–1.80)         |
| **Drinking, current**                  |                     |                 |                        |                          |
| No                                     | 322 (72.9)          | 120 (27.2)      | 1.00                   | 1.00                     |
| Yes                                    | 53 (75.7)           | 17 (24.3)       | 0.86 (0.48–1.55)       | 0.62 (0.32–1.20)         |

Abbreviations: N number, y year, OR odds ratio, CI confidence interval.

*Adjusted for all variables in univariate analysis.
Our results show that screen-detected cancer survivors are approximately twice more likely to receive all appropriate SPC screening, even after controlling for other covariates which may affect cancer screening behaviors. Therefore, the mode of primary cancer detection separates two subpopulations of cancer survivors with differing risk for not receiving proper SPC screening, serving as a clinical indicator.

According to the Health Belief Model (HBM), people will take action to prevent, screen for, or control their health conditions if they believe they are susceptible, believe the condition would have serious consequences, and believe there is benefit to taking a course of action [24]. The role of better knowledge [25,26], a positive attitude [27], and perceived risk [28] in cancer screening practices are well known in the general population.

Similar findings have been reported in cancer survivors regarding SPC screening about the role of knowledge [12] and risk perception of SPC [11,12]. It was reported that cancer survivors often could not differentiate SPC from “recurrence” or “metastasis,” and could not make a distinction between “cancer screening” and “routine surveillance test” after cancer treatment [29]. Such lack of knowledge [12] was significantly associated with failed completion of all appropriate SPC screening in cancer survivors. In addition, a considerable portion of cancer survivors perceived their cancer risk as lower than that of the general population, and such misperception of SPC risk were negatively associated with screening for SPC. While those studies provide theoretical insight on the screening behavior of cancer survivors, it is impractical to collect information regarding their knowledge and risk perception in the clinical setting, their clinical utility being limited.

We suspect that the mode of primary cancer detection could be an indicator of such knowledge or risk perception of SPC in cancer survivors for the following reasons. First, people who generally have good knowledge on the benefit of cancer screening and proper risk perception are more likely to receive cancer screening, and in case they are diagnosed with cancer, they are most likely to become screen-detected cancer survivors. Second, the personal experience of discovering their cancer through screening would provide the knowledge that screening is critical to early detection and effective treatment of cancer. Unfortunately, our survey did not include specific questions about the cancer survivors’ knowledge and risk perception, therefore, our explanation for the association can only remain hypothetical.

It is interesting to note one of our observations that having been diagnosed with primary cancer for more than 5 years is associated with being non-screen-detected (Table 4). This can be attributed to the recently developed and propagated national cancer screening program in Korea which, launched in 1999, has successfully increased its participation rate from 12.7% in 2002 to 27.8% in 2008, and is projected to have increased further [30]. As our survey has been carried out in 2008, our observations reflect such drastic changes in national screening rates.

The rate of liver or lung cancer survivors to be screen-detected has been shown to be overall higher than that of stomach, colorectal, breast, or cervical cancer survivors, which are cancer types with specific screening recommendations (Table 4). This may be interpreted as counterintuitive and we have two main explanations for these observations. One, considering our study excluded subjects with less than 2 years since diagnosis, recurrence, or distant disease, and also considering the relatively high 5-year mortality rate of lung or liver cancer in Korea [31], we suspect there is a selection bias toward screen-detected lung or liver cancer survivors. Two, early detection of lung or liver cancer involves low dose chest computed tomography or abdomen ultrasonography, respectively, which are procedures in Korea only offered (to asymptomatic subjects without particular indications) in commercial private health screening programs, but not in government screening programs that strictly abide to specific screening recommendations [32]. Therefore, mostly health-conscious subjects are exclusively willing to pay the high price for such health packages, a phenomenon not unique in Korea [33]. This would be a source of selection bias not exclusive to our study, but to lung or liver cancer survivors (with more years since diagnosis) in general, that well explains such aforementioned counterintuitive observations. We regard these observations to be very interesting, because a further study on the particular nature of mode of primary cancer detection (whether it be screening via government programs or commercial programs) and its association to completion of all appropriate SPC screening will most likely add predictive value to identifying high risk cancer survivors at risk of not properly receiving proper SPC screening.

It is to be emphasized that our results and implications are especially significant in that we considered completion of all appropriate SPC screening rather than single type SPC screening. Most previous studies investigating the barriers associated to screening have evaluated screening of single, specific cancer types [17,22], and according to a large US study, only 3% of women and 5% of men older than 50 had completed all appropriate cancer screening for their age and sex [34]. This fact should be noted in context to 1) various public campaigns for single type cancer screening, as in the case of pink ribbon breast cancer campaign [35], and 2) many practices that provide only one or two screening tests. In fact, in our results, compared to stomach cancer
survivors, breast cancer survivors were significantly associated to non-completion of all appropriate SPC screening (aOR 0.31, 95% CI 0.15–0.64; Table 3). We therefore assert that analysis of factors associated with completion of all appropriate SPC screening would more accurately reflect cancer survivors’ knowledge and perception of SPC screening, and hence be better predictive of their SPC screening behavior, than that of single type SPC screening.

There are several limitations to our current study. First, there is a source of imprecision in terms of the definition of SPC screening in our sample and its correspondence to time since diagnosis, especially for colorectal cancer screening. Due to limitation of sample size, our analysis includes cancer survivors with time since diagnosis from 2 years and more. Because colorectal cancer screening guidelines recommend screening every 5 years after age 50, those with time since diagnosis less than 5 years (and older than 50) may not have been subject to SPC screening for colorectal cancer and consequently, we may have accounted for primary cancer screening. However, sensitivity analysis (data not shown) among patients with time since diagnosis beyond 5 years show similar magnitude of association and statistical significance of factors associated with completion of all appropriate SPC screening. Second, the assessment of cancer screening practices was based on participants' self-report, subject to recall bias. Although we used carefully phrased questions which were used in KNHANES [14] to maximize accuracy, it is possible that survivors with less knowledge may have also had more difficulty understanding the questions correctly or may have undergone screening tests without realizing that they were performed for screening purposes. Third, despite of our study's multicenter, nationwide design, our study sample was not large enough to allow subgroup analysis by primary cancer type. It is possible that the behaviors may differ among survivors with different primary cancers. Fourth, we cannot statistically assess the representativeness of our sample. Instead, we employed quota sampling to obtain a similar distribution of cancer types to the general Korean cancer population. In addition, our gender and age group distributions were not biased. Overall, we assert that this limitation does not lead to serious problems with internal validity or representation, and there has been previous studies based on the same survey [36].

Despite above-mentioned limitations, our study suggests that the mode of primary cancer detection, a readily available clinical information, can be used as an indicator for screening practice for SPC in cancer survivors. Education about the importance of SPC screening will be helpful particularly for cancer survivors whose primary cancer was not screen-detected.

Conclusions

We have identified non-screen-detected cancer survivors as a subgroup at risk of improper SPC screening behavior. We suggest that all cancer survivors must be inquired about how their primary cancer were detected, and extensive emphasis and education on the importance of SPC screening must be provided, especially, for non-screen-detected cancer survivors by their physicians in the clinic.

Competing interests

All authors have no potential financial, professional or personal conflicts by publishing this manuscript. J-H. Park was supported by a research grant from National Cancer Center Grant No. 0910191 & 1210151, Korea. This government organization had no influence on any aspect relevant to this study.

Authors' contributions

DWS and JHP conceived of the study, participated in design and coordination of the study. DWS, JHP, YWC, SPL, CYY were involved in acquisition of data. BS performed the statistical analysis and drafted the manuscript. DWS, JHP, SYK, BLC, ECP gave administrative support, and reviewed the manuscript. All authors read and approved the final manuscript.

Author details

1Department of Family Medicine & Health Promotion Center, Seoul National University Hospital, Seoul, Republic of Korea. 2Cancer Survivorship Clinic, Seoul National University Cancer Hospital, 101 Daehak-ro, Jongno-Gu, Seoul 110-744, Republic of Korea. 3Division of Cancer Policy and Management, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea. 4Department of Social and Preventive Medicine, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea. 5Department of General Surgery, Cheju Regional Cancer Center, Cheju National University Hospital, Jeju, Republic of Korea. 6Department of Thoracic and Cardiovascular Surgery, Daejon Regional Cancer Center, Chungnam National University Hospital, Daejeon, Republic of Korea. 7Division of Hematology-Oncology, Jeonbuk Regional Cancer Center, Chorubuk National University Hospital, Jeonju, Republic of Korea. 8Department of Preventive Medicine & Institute of Health Services Research, Yonsei University College of Medicine, Seoul, Republic of Korea. 9Division of Cancer Policy and Management, National Cancer Control Research Institute, National Cancer Center, 111 Jungbalsan-ro, Ilsan-dong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea.

Received: 8 June 2012 Accepted: 16 November 2012 Published: 26 November 2012

References

1. Weir HK, Thun MJ, Hankey BF, Ries LAG, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK: Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2005, 97(17):1276–1299.
2. Horner M, Ries L, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse S, Feuer E, Huang L, Mariotto A (Eds): SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute, 2009.
3. Hewitt ME, Greenfield S, Stovall E: From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academy Press, 2006.
4. Curtis RE, Freedman DM, Ron E, Ries LAG, Hatcher DG, Edwards BK, Tucker MA, Fraumeni JF Jr: New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. In, National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD: 2006.
5. Park SM, Lim MK, Jung KW, Shin SA, Yoo K-Y, Yun YH, Huh BY: Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 2007, 25(30):4835–4843.
6. Schapveld M, Visser O, Louwman MJ, de Vries EGE, Willemsen PHB, Otter R, van der Graaf WTA, Coebergh JWW, van Leeuwen FE: Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 2008, 26(8):1239–1246.
7. Bellizzi KM, Rowland JH, Jeffery EO, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol 2005; 23(5):8884–8893.
8. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003; 21(6):1147–1151.
9. Teck PC, Rabkin C, Rogers ML, Whitely, J, Nash J, Frierson G, Pinto B. Cancer screening practices among cancer survivors. Am J Prev Med 2005; 28(4):351–356.
10. Cho J, Guallar E, Hsu YJ, Shin DW, Lee WC. A comparison of cancer screening practices in cancer survivors and in the general population: the Korean national health and nutrition examination survey (KNHANES) 2001–2007. Cancer Causes Control 2010; 21(12):2003–2012.
11. Park SM, Park CT, Park SY, Bae DS, Nam JH, Cho CH, Lee JM, Earle CC, Yun YH. Factors related to second cancer screening practice in disease-free cervical cancer survivors. Cancer Causes Control 2009; 20(9):1697–1703.
12. Shin DW, Kim YW, Oh JH, Kim SW, Chung KW, Lee WY, Lee JE, Lee WC, Guallar E, Cho J. Knowledge, attitudes, risk perception, and cancer screening behaviors among cancer survivors. Cancer 2011; 117(6):3850–3859.
13. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. In, National Cancer Institute, NIH Pub. No. 01-4969 Bethesda, MD; 2001.
14. Center for Disease Control and Prevention & Korean Institute for Health and Social Affairs; 2007. In-depth analyses of the third national health and nutrition examination survey: the health interview and health behavior survey section. Seoul, Republic of Korea: Center for Disease Control and Prevention & Korean Institute for Health and Social Affairs, 2007.
15. Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol 2008; 38(5):327–333.
16. Kwon YM, Park EC, Bang JY, Sung NY, Lee JY, Choi KS. Factors associated with cancer screening practice, Korea. J Prev Med Public Health = Yeolbang nakhoe chi 2005; 38(4):473–481.
17. Lee K, Lim H, Park S. Factors associated with use of breast health screening services by women aged ≥ 40 years in Korea: The Third Korean National Health and Nutrition Examination Survey 2005 (KNHANES III). BMC Cancer 2010; 10:1-144.
18. Wardle J, Miles A, Atkin W. Gender differences in utilization of colorectal cancer screening. J Med Screen 2005; 12(1):20–27.
19. Duffy CM, Clark MA, Allowoth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prevent 2006; 30(1):52–57.
20. Sheen V, Tucker MA, Abramson DH, Seddon JM, Kleinerman RA. Cancer screening practices of adult survivors of retinoblastoma at risk of second cancers. Cancer 2008; 113(2):434–441.
21. Fukudou Y, Nakamura K, Takano T, Nakao H, Imai H. Socioeconomic status and cancer screening in Japanese males: large inequality in middle-aged and urban residents. Environ Health Prev Med 2007; 12(2):90–96.
22. Kwon YM, Lim HT, Lee K, Cho BL, Park MS, Son KY, Park SM. Factors associated with use of gastric cancer screening services in Korea. World J Gastroenterol 2009; 15(28):3653–3659.
23. Snyder CF, Fick KD, Kantorier ME, Peairs KS, Herbert RJ, Blackford AL, Wolff AC, Earle CC. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 2009; 27(7):1054–1061.
24. Hayden J. Introduction to health behavior theory. Burlington: Jones & Bartlett Learning; 2009.
25. Sung JF, Blumenthal DS, Coates RJ, Almora-Mensah E. Knowledge, beliefs, attitudes, and cancer screening among inner-city African-American women. J Natl Med Assoc 1997; 89(6):405–411.
26. Pearlman DN, Clark MA, Rakowski W, Ehrich B. Screening for Breast and Cervical Cancers: The Importance of Knowledge and Perceived Cancer Survivability. Women Health 1999; 28(4):193–112.
27. Cullati S, Charvet-Bérand A, Peneger T. Cancer screening in a middle-aged general population: factors associated with practices and attitudes. BMC Public Health 2009; 9(1):118.
28. Bloom JR, Stewart SL, Oakley-Girvans I, Banks PJ, Chang S. Family history, perceived risk, and prostate cancer screening among African American men. Cancer Epidemiol Biomarkers Prev 2006; 15(11):2167–2173.
29. Shin DW, Baik YJ, Kim JW, Oh JH, Chung K-W, Kim SW, Lee W-C, Yun YH, Cho J. Knowledge, attitudes, and practice on second primary cancer screening among cancer survivors: A qualitative study. Patient Educ Couns 2011; 85(1):74–78.
30. Kim Y, Jun JK, Choi KS, Lee HY, Park EC. Overview of the national cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev 2011; 12:225–730.
31. Jung KW, Park S, Kang HI, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2006–2007. J Korean Med Sci 2010; 25(8):1113–1121.
32. Kang S, You CH, Kwon YD: The Determinants of the Use of Opportunistic Screening Programs in Korea. J Prev Med Public Health 2009, 42(6):177–182.
33. Emmons KM, Cleghorn D, Tellez T, Greaney ML, Spruick KM, Bastani R, Battaglia T, Michaelson JS, Puleo E. Prevalence and implications of multiple cancer screening needs among Hispanic community health center patients. Cancer Causes Control 2011; 22(9):1343–1349.
34. Ruffin M, Gorenflo D, Woodman B. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices. J Am Board Fam Pract 2000, 13(1):1–10.
35. Zurek M, Touboul PJ, Bonithon-Kopp C, Courbon D, Rueland I, Ducimetière P. Differential association of common carrotid intima-media thickness and carotid atherosclerotic plaques with parental history of premature death from coronary heart disease: the EVA study. Atherosclerosis Thromb Vasc Biol 1999; 19(2):366–371.
36. Eom CS, Shin DW, Kim SY, Yang HK, Jo HS, Kweon SS, Kang YS, Kim JH, Cho Bl, Park JH. Impact of perceived social support on the mental health and health-related quality of life in cancer patients: results from a nationwide, multicenter survey in South Korea. Psychooncology, in press.